MEDIPOST Past Earnings Performance
Past criteria checks 1/6
MEDIPOST has been growing earnings at an average annual rate of 45.3%, while the Healthcare industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 10.5% per year. MEDIPOST's return on equity is 1.1%, and it has net margins of 6.6%.
Key information
45.3%
Earnings growth rate
43.5%
EPS growth rate
| Healthcare Industry Growth | 34.2% |
| Revenue growth rate | 10.5% |
| Return on equity | 1.1% |
| Net Margin | 6.6% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To MEDIPOST Co., Ltd. (KOSDAQ:078160) With Shares Advancing 29%
Nov 04
Is MEDIPOST (KOSDAQ:078160) Using Debt Sensibly?
Aug 06MEDIPOST's (KOSDAQ:078160) Attractive Earnings Are Not All Good News For Shareholders
Mar 27Is MEDIPOST (KOSDAQ:078160) Weighed On By Its Debt Load?
Mar 11MEDIPOST's (KOSDAQ:078160) Stock Price Has Reduced 32% In The Past Three Years
Jan 17Is MEDIPOST (KOSDAQ:078160) A Risky Investment?
Nov 24Revenue & Expenses Breakdown
How MEDIPOST makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 70,009 | 4,589 | 34,821 | 35,739 |
| 31 Mar 24 | 69,145 | 5,265 | 33,855 | 31,899 |
| 31 Dec 23 | 68,643 | 5,840 | 34,115 | 29,216 |
| 30 Sep 23 | 68,152 | -590 | 33,050 | 25,708 |
| 30 Jun 23 | 67,056 | 18,216 | 36,029 | 22,748 |
| 31 Mar 23 | 66,355 | 3,300 | 36,377 | 20,562 |
| 31 Dec 22 | 64,201 | 3,069 | 35,017 | 19,004 |
| 30 Sep 22 | 62,413 | 2,769 | 33,438 | 16,498 |
| 30 Jun 22 | 59,321 | -13,259 | 28,272 | 14,433 |
| 31 Mar 22 | 57,213 | -1,363 | 25,014 | 13,103 |
| 31 Dec 21 | 54,856 | -683 | 23,568 | 11,703 |
| 30 Sep 21 | 52,853 | -5,361 | 22,372 | 10,822 |
| 30 Jun 21 | 51,463 | -10,511 | 22,015 | 10,862 |
| 31 Mar 21 | 49,406 | -11,712 | 21,508 | 10,238 |
| 31 Dec 20 | 48,625 | -1,896 | 21,663 | 9,443 |
| 30 Sep 20 | 46,866 | -17,014 | 21,954 | 9,848 |
| 30 Jun 20 | 46,169 | -13,016 | 22,092 | 11,884 |
| 31 Mar 20 | 45,718 | -10,499 | 22,669 | 12,403 |
| 31 Dec 19 | 45,811 | -14,120 | 22,770 | 12,661 |
| 30 Sep 19 | 45,690 | 2,851 | 22,956 | 11,839 |
| 30 Jun 19 | 45,475 | 2,923 | 22,769 | 9,465 |
| 31 Mar 19 | 45,214 | 1,385 | 22,811 | 9,115 |
| 31 Dec 18 | 44,384 | -2,007 | 24,010 | 9,325 |
| 30 Sep 18 | 44,745 | -3,938 | 22,704 | 9,415 |
| 30 Jun 18 | 43,085 | -5,471 | 22,886 | 8,669 |
| 31 Mar 18 | 44,091 | -4,616 | 22,134 | 8,006 |
| 31 Dec 17 | 42,250 | -950 | 19,669 | 7,371 |
| 30 Sep 17 | 37,848 | -7,924 | 19,053 | 13,377 |
| 30 Jun 17 | 35,198 | -6,705 | 18,153 | 12,585 |
| 31 Mar 17 | 30,268 | -9,988 | 18,623 | 12,239 |
| 31 Dec 16 | 28,654 | -11,196 | 18,336 | 11,491 |
| 30 Sep 16 | 29,468 | -4,596 | 17,948 | 3,823 |
| 30 Jun 16 | 31,839 | -4,193 | 18,357 | 3,622 |
| 31 Mar 16 | 35,131 | 51 | 17,693 | 2,965 |
| 31 Dec 15 | 37,570 | 2,779 | 17,876 | 2,580 |
| 30 Sep 15 | 45,294 | 3,332 | 18,337 | 2,576 |
| 30 Jun 15 | 45,769 | 3,752 | 17,736 | 2,377 |
| 31 Mar 15 | 44,058 | 1,363 | 17,703 | 2,086 |
| 31 Dec 14 | 41,403 | -1,851 | 17,266 | 2,085 |
| 30 Sep 14 | 39,697 | -1,838 | 16,811 | 2,109 |
| 30 Jun 14 | 39,288 | -122 | 16,955 | 2,068 |
| 31 Mar 14 | 40,210 | -1,177 | 16,763 | 2,276 |
| 31 Dec 13 | 41,504 | 996 | 16,930 | 2,087 |
Quality Earnings: A078160 has a large one-off gain of ₩6.2B impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: A078160's current net profit margins (6.6%) are lower than last year (27.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A078160 has become profitable over the past 5 years, growing earnings by 45.3% per year.
Accelerating Growth: A078160's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A078160 had negative earnings growth (-74.8%) over the past year, making it difficult to compare to the Healthcare industry average (8.3%).
Return on Equity
High ROE: A078160's Return on Equity (1.1%) is considered low.